What 20 years of research has taught us about the TP53 p.R337H mutation

Abstract

The p53 tumor suppressor transcriptionally regulates a myriad of genes involved in cell cycle control, DNA repair, cell survival, and cell metabolism and represents one of the most well-studied inhibitors of tumorigenesis. Since the discovery of TP53 in 1979, somatic mutations have been shown to be extremely common; more than 50% of human cancers carry loss-of-function mutations in TP53. Inherited or germline TP53 mutations are rare and are involved in complex hereditary cancer predisposition disorders, and affected family members can develop diverse tumor types and multiple primary cancers at young ages. In Brazil, a fascinating history of p53 and cancer predisposition began in the year 2000 with identification of the TP53 p.R337H mutation in close association with the development of adrenocortical tumors. In these past 20 years, much has been learned about the genetics and biochemistry of this mutation, which is widespread in Brazil because of a founder effect. This review highlights the contributions of TP53 p.R337H research over the last 20 years, the findings of which have sparked passionate debate among researchers worldwide, to understanding cancer predisposition in Brazilian individuals and families. Cancer 2020;126:4678-4686.

Integrated Molecular Docking with Network Pharmacology to Reveal the Molecular Mechanism of Simiao Powder in the Treatment of Acute Gouty Arthritis

“…TP53, FN1, ESR1, CDK2, and HSPA5 were the five core target proteins. Based on the existing reports, TP53, also known as p53, contributes to transcriptional regulation of the cell cycle, DNA repair, cell survival, and cell metabolism [ 35 ]. Inhibition of p53 exerts a substantial effect on promoting the senescence of IL-1 β -induced chondrocytes [ 36 ].…”

Mutant p53 in cell-cell interactions

“…Missense mutations in the N-terminal domain and C-terminal oligomerization domain (OD), which flank the DBD of p53, are also found in human cancers, although somatic alterations in this region are less frequent. Interestingly, the R337H OD alteration is found in a significant number of LFS families in southern Brazil (Pinto and Zambetti 2020).…”

ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms

“…A precursor lesion with loss of ARID1A expression might cause a premalignant lesion of cholangiocarcinoma. TP53, also known as P53, is one of the most frequent genetic variants in human cancers, which plays a key role in the control of the cell cycle, apoptosis, and DNA repair (55). Alteration of PT53 is a prognostic biomarker for cancer due to its biological function of carcinogenesis.…”